AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
enGene Holdings Inc.
Video analysis: ENGN
All videosNo video analysis for this stock yet. Request one from our team.
News: ENGN
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk due to weak 12-month durability, but management is pursuing a surfactant cohort to address efficacy. Cost-saving measures, including a 50% workforce reduction, extend ENGN's cash runway into 2029, supporting operations through pivotal BLA milestones.
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. “As we move through the second half of 2026, our focus is on maturing regulatory endpoints data from LEGEND's pivotal cohort and our planned engagement with the FDA regarding a BLA filing for detalimogene," said Ro.
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8, 2026 Time: 10:15 a.m. ET Format: Fireside Chat Morgan Stanley 24th Annual Global Healthcare Conference Date: Monday, September 14, 2026 Time: 7:00 a.m. ET Format: Fireside Chat H.
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 64.2% of enGene shares are
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy.
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations dr.
